Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Sarcoma 3Sarcoma, Synovial 2Rhabdomyosarcoma 2Neurofibrosarcoma 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Hemangiosarcoma 2Fibrosarcoma 2Triple Negative Breast Neoplasms 1Sarcoma, Alveolar Soft Part 1Ovarian Neoplasms 1Malignant mesenchymal tumor 1Liposarcoma, Myxoid 1Hemangiopericytoma, Malignant 1Gastrointestinal Stromal Tumors 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × brostallicin × Clear all
NCT01091454 2018-05-08

Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
48 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡